The Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale is a 36-item self-report instrument that measures multidimensional quality of life. It was developed from 1987-1993 and first published in 1995. The FACT-L meets a growing need for disease-specific health-related quality of life (HRQOL) questionnaires that address the general and unique concerns of patients diagnosed with lung cancer. Subsequent to its development, its results have been published in over 25 papers from over 15 unique data sets including over 4,000 people with lung cancer. Since 1995, studied groups have included cancer patients receiving chemotherapy, cancer patients receiving radiotherapy, terminally-ill patients and disease-free survivors. It is a widely-used, reliable and valid measure of multidimensional health status among people with lung cancer. It is brief, has clearly-written, easy-to-read questions, flexible modes of administration shown to be equivalent, and is translated in several dozen languages.
Functional Assessment of Cancer Therapy – Lung (FACT-L)
NUMBER OF ITEMS:
Lung cancer patients 18 years and older
Past 7 days
5 point Likert-type scale
Paper and electronic
Self-administration and interview when applicable
Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Lung Cancer Subscale
TIME FOR COMPLETION:
Manual scoring template, some items are reverse scored. Subscale scores, total scores and TOI scores possible. SAS/SPSS algorithms available.
Available translations of the FACT-L can be obtained by registering for permission. Users are not permitted to translate the FACT-L without permission from FACIT.org. Permission from FACIT.org to translate the FACT-L may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system.
Please contact us for more information.
Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained.
Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use.
To license an available version of this measure for commercial or non-commercial use, please complete our registration form. All of the information provided in the form will be kept strictly confidential. For questions, please contact us.
Butt, Z., Webster, K., Eisenstein, A., Beaumont, J., Eton, D., Masters, G., & Cella, D. Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy – Lung Scale. Hematology/Oncology Clinics of North America 2005; 19: 389-420. doi: 10.1016/j.hoc.2005.02.009.
Cella, D., Eton, D., Hensing, T., Masters, G., & Parasuraman, B. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clinical Lung Cancer 2008; 9(1): 51-58. doi: 10.3816/CLC.2008.n.009.
Cella, D.F., Bonomi, A.E., Lloyd S.R., Tulsky, D.S., Kaplan, E., & Bonomi, P. Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12: 199-220.
Chang, C, Cella, D., Masters, G.A., Laliberte, N., O’Brien P., Peterman, A., & Shevrin, D. Real-time clinical application of quality of life assessment in Lung Cancer. Clinical Lung Cancer 2002; 4(2): 104-109. doi: 10.3816/CLC.2002.n.020.
Davis, K., Yount, S., Del Ciello, K., Whalen, M., Khan, S., Bass, M., Du, H., Eton, D., Masters, G., Hensing, T., & Cella, D. An innovative symptom monitoring tool for people with advanced lung cancer: A pilot demonstration. Journal of Supportive Oncology 2007; 5(8): 381-387.
Juliana, F., Jardim, J., Fernandes, A., Jamnik, S., & Santoro, I. Reliability of the Brazilian version of the Functional Assessment of Cancer Therapy-Lung (FACT-L) and the FACT-Lung Symptom Index (FLSI). Clinics 2010; 65(12):1247-1251. doi: :10.1590/S1807-59322010001200005.
Jennifer S. Temel, J., Greer, J., Muzikansky, A., Gallagher, E., Admane, S., Jackson, V., Dahlin, C., Blinderman, C., Jacobsen, J., Pirl, W., Billings, J. & Lynch, T. Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer. The New England Journal of Medicine 2010; doi: 363:733-742. 10.1056/NEJMoa1000678.
Yaskevich, V., Marochkova, V., Nikitins, G., & Sharf, I. The Influence of anesthesia type on the life qualify of women after radical mastectomy. VESTNIK VITEBSKOGO GOSUDARSTVENNOGO MEDITSINSKOGO UNIVERSITETA 2017; 16(2): 85-90. doi: 10.22263/2312-4156.2017.2.85.
Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320.
Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232.
Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85.
Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191.
National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 17 Item Version